Download the White Paper describing how continuous aseptic freeze-drying can address the major pain points of pharmaceutical batch freeze-drying
News
The paradigm shift from batch to continuous manufacturing
After more than 50 years it is time for a paradigm shift.
We have created a White Paper describing how continuous aseptic freeze-drying can address the major pain points of pharmaceutical batch freeze-drying such as: time-consuming, inefficient, energy-consuming, and poorly controlled.
With a special case study from the company simAbs on the continuous manufacturing process that consistently produces high-quality Drug Substance of monoclonal antibodies.
For the most up to date news, please follow us on LinkedIn via the link below
Download the White Paper on "Stabilizing mRNA LNPs via controlled, continuous freeze-drying"
News
Stabilizing mRNA LNPs via controlled, continuous freeze-drying
Lyophilization is considered to be one of the most promising approaches to stabilize mRNA-LNP formulations and enhance their stability at refrigerated or even room temperatures.
However, lyophilization is a slow, expensive, poorly controlled, and labor-intensive process. Consequently, these disadvantages hamper the fast and cost-efficient development of mRNA-LNP vaccines.
Download the White Paper describing the advantages associated with a RheaVita’s NextGen continuous and controlled lyophilization. This drying technology allows the R&D team and the MSAT team to save money and staffing. It opens a path for seamless scaling-out without the need to reformulate lyophilization protocols. All this may result in a faster time to the market for your mRNA drug or vaccine.
For the most up to date news, please follow us on LinkedIn via the link below